Biotech & Biopharmaceuticals
Research-stage and commercial biotechnology companies developing large molecule therapeutics, cell and gene therapies, and novel biological treatments for disease.
- 5
- Verticals
Overview
Biotech & Biopharmaceuticals covers research-stage and commercial companies developing small-molecule, large-molecule, cell, and gene therapies. It is the innovation engine of healthcare (high-risk, high-reward, R&D-intensive, and the source of the industry's growth), spanning big pharma, mid-cap biopharma, and a vast emerging-biotech ecosystem.
M&A is structural and constant: big pharma faces a wave of patent cliffs (loss of exclusivity on major drugs) and acquires biotech to replenish pipelines, while the GLP-1/obesity franchise (Novo Nordisk, Eli Lilly) has reshaped the sector's growth and valuations. U.S. manufacturing receipts understate the global, IP-driven economics.
Market snapshot
- Market size
- ~$211B
- Growth
- ~1.4%CAGR (2017–22, nominal)
- Companies
- ~2,181 firms
58.2% of firms have fewer than 20 employees: 1,269 micro-businesses, below most mandates.
- 20–99
- 40344%
- 100–499
- 26829%
- 500+
- 24126%
U.S. biopharma manufacturing: ~2,180 firms, extraordinarily asset- and IP-heavy (payroll just 13% of revenue, ~$97M revenue per firm). The ~$211B is U.S. manufacturing receipts; the global, patent-driven market is far larger. Measured growth was slow (~1.4%/yr) because the value sits in IP and pipeline, not domestic production volume. M&A, meanwhile, runs hot, driven by patent cliffs and the GLP-1 boom.
NAICS 325411, 325412, 325414. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.
Business model & economics
Revenue model
Patent-protected drug sales and royalties
Key economics
- Revenue per firm
- $96,794,531
- Revenue per employee
- $804,188
- Employees per firm
- 125.3
- Recurring revenue
- Moderate
- EBITDA margin
- High for branded on-patent drugs
- Capex intensity
- High
on-patent franchises; cliffs reset it
Characteristics
- Scale-driven: payroll is only 13% of revenue, so the cost base is assets, not headcount
- Deep strategic-buyer pool: 241 firms exceed 500 employees, so a scaled asset has trade buyers
- The innovation engine of healthcare: high-risk, R&D-intensive.
- Patent cliffs drive constant pipeline-replenishing M&A.
- GLP-1/obesity franchise reshaped sector growth.
NAICS 325411, 325412, 325414. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.
Geographic concentration
Biotech and biopharmaceutical operations concentrate in the established life-sciences clusters of California (the Bay Area and San Diego), Massachusetts (Greater Boston), and North Carolina's Research Triangle. These are by far the largest centers of industry employment.
U.S. Census Bureau, 2022 County Business Patterns (employment by state), NAICS 325411/325412/325414. Leading states by biopharmaceutical employment.
M&A deal context
Who’s acquiring
- Big pharma & biopharma strategics
- Biotech-acquiring platforms
- VC- and crossover-backed biotech
What’s driving deals
- Patent-cliff-driven acquisition of biotech pipelines.
- GLP-1 and novel-modality competition.
- Biotech funding cycles and platform deals.
Verticals in this segment
Find Biotech & Biopharmaceuticals acquisition targets
Search Acquisera’s index for companies classified under Biotech & Biopharmaceuticals (4.9.1) and build a targeted deal pipeline.
Search companies